Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 2004 Jun-Sep;8(2-3):57–61. doi: 10.1080/13577140412331332785

The Role of Irradiation in the Management of Locally Recurrent Non-Metastatic Soft Tissue Sarcoma of Extremity/Trunkal Locations

James Fontanesi 1,7,✉, Michael P Mott 2, David R Lucas 3, Peter R Miller 5,6, Michael J Kraut 4
PMCID: PMC2395609  PMID: 18521396

Abstract

Background: Patients who have had initial curative intent therapy for non-metastatic soft tissue sarcoma, and who subsequently relapse at the initial site without evidence of metastatic disease, have various options regarding local treatment. The treatment options available will be determined by the extent of relapse, previous therapy rendered, and patient characteristics. We reported on a series of 31 patients treated initially with only surgery for extremity/trunkal high-grade soft tissue sarcoma and then seen for recurrence at our institution between 1980 and 1999. Local re-treatment consisted of combined modality therapy, most often aggressive surgical debulking/resection and irradiation, in an effort to reduce the need for amputation and, where anatomically allowable, to maintain a functional limb. We report our results in re-establishing local control, subsequent survival, and complication rates.

Methods: Thirty-one patients with locally recurrent, non-metastatic high-grade soft tissue sarcoma, (excluding extraabdominal desmoid) were retrospectively reviewed to determine local control, survival, and complication rates associated with the relapsed disease. All patients had multimodality re-treatment most often utilizing aggressive surgical debulking and irradiation. The irradiation consisted of either external beam alone, brachytherapy alone, or a combination of external beam and brachytherapy. Nine patients also received multi-agent, multi-cycle chemotherapy using various regimens. In addition, the impact of surgical margin at the time of re-resection (gross versus microscopic disease), radiation treatment type, total radiation dose delivered, size of relapse, histological sub-type, sex and age, were evaluated to determine if they had any impact on the re-establishment of local control and subsequent survival.

Results: Local control was re-established in 25 of 31 (80.6%) patients. Two additional patients with isolated local relapse after irradiation were salvaged with amputation and remain NED at last follow-up. With these patients a total of 27/31 (87%) are now with local control. At last follow-up, which ranged from 23 to 192 months, 23 of 31 (74%) remained alive. Of the eight patients who have died, four had evidence of local and distant failure. Two additional patients died of distant failure while the treated sites remained in local control and two patients, both NED, died of intracurrent processes. Follow-up for those patients who had re-established local control has ranged from 23 to 192 months (median=60.5 months). Time to local failure following re-treatment ranged between 3 and 72 months following re-treatment (median=12 months). Five patients had significant treatment related complications. Included are two patients in which amputation was required due to local recurrences. Two patients developed a soft tissue necrosis and one patient had a wound healing problem that resolved with conservative management. No statistical significance in the development of local control could be found based on surgical margin status, total dose of irradiation (greater or less than 60 Gy), size of recurrence (greater than 5 cm), histological sub-type, sex, or age (greater than 50 years). There was a trend for negative impact for those patients receiving only external beam irradiation.

Conclusion: Selective locally recurrent, non-metastatic soft tissue sarcoma of the extremity/trunkal regions should still be considered eligible for aggressive limb-sparing therapy. Our experience suggests that a majority of patients re-establish local control following aggressive surgical resection/debulking and irradiation and this appears to be durable in its nature. The role of chemotherapy in this group of patients remains investigational. In a surprising finding, one patient re-relapsed in the re-treatment site at 72 months, thus justifying continued strict surveillance not only in the primary site but also for subsequent metastatic disease.

Full Text

The Full Text of this article is available as a PDF (55.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alektiar K. M., Velasco J., Zelefsky M. J., Woodruff J. M., Lewis J. J., Brennan M. F. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1051–1058. doi: 10.1016/s0360-3016(00)00753-7. [DOI] [PubMed] [Google Scholar]
  2. Baldini E. H., Goldberg J., Jenner C., Manola J. B., Demetri G. D., Fletcher C. D., Singer S. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999 Oct;17(10):3252–3259. doi: 10.1200/JCO.1999.17.10.3252. [DOI] [PubMed] [Google Scholar]
  3. Benjamin R. S. Evidence for using adjuvant chemotherapy as standard treatment of soft tissue sarcoma. Semin Radiat Oncol. 1999 Oct;9(4):349–351. doi: 10.1016/s1053-4296(99)80028-9. [DOI] [PubMed] [Google Scholar]
  4. Eilber Fritz C., Rosen Gerald, Nelson Scott D., Selch Michael, Dorey Frederick, Eckardt Jeffery, Eilber Frederick R. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003 Feb;237(2):218–226. doi: 10.1097/01.SLA.0000048448.56448.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gibbs J. F., Lee R. J., Driscoll D. L., McGrath B. E., Mindell E. R., Kraybill W. G. Clinical importance of late recurrence in soft-tissue sarcomas. J Surg Oncol. 2000 Feb;73(2):81–86. doi: 10.1002/(sici)1096-9098(200002)73:2<81::aid-jso5>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  6. Henshaw R. M., Priebat D. A., Perry D. J., Shmookler B. M., Malawer M. M. Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol. 2001 Jul;8(6):484–495. doi: 10.1007/s10434-001-0484-8. [DOI] [PubMed] [Google Scholar]
  7. Issels R. D., Schlemmer M. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol. 2002 Apr 16;49 (Suppl 1):S4–S8. doi: 10.1007/s00280-002-0445-3. [DOI] [PubMed] [Google Scholar]
  8. Janjan Nora, Crane Christopher, Delclos Marc, Ballo Matthew. Brachytherapy for locally recurrent soft-tissue sarcoma. Am J Clin Oncol. 2002 Feb;25(1):9–15. doi: 10.1097/00000421-200202000-00002. [DOI] [PubMed] [Google Scholar]
  9. Khanfir K., Alzieu L., Terrier P., Le Péchoux C., Bonvalot S., Vanel D., Le Cesne A. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur J Cancer. 2003 Sep;39(13):1872–1880. doi: 10.1016/s0959-8049(03)00426-x. [DOI] [PubMed] [Google Scholar]
  10. Lewis J. J., Leung D., Heslin M., Woodruff J. M., Brennan M. F. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997 Feb;15(2):646–652. doi: 10.1200/JCO.1997.15.2.646. [DOI] [PubMed] [Google Scholar]
  11. O'Sullivan Brian, Pisters Peter W. Staging and prognostic factor evaluation in soft tissue sarcoma. Surg Oncol Clin N Am. 2003 Apr;12(2):333–353. doi: 10.1016/s1055-3207(03)00011-5. [DOI] [PubMed] [Google Scholar]
  12. Ottaiano A., De Chiara A., Fazioli F., De Rosa V., Ravo V., Boccia V., Botti G., Petrillo A., Fiore F., Mori S. Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide. Anticancer Res. 2002 Nov-Dec;22(6B):3555–3559. [PubMed] [Google Scholar]
  13. Petrioli Roberto, Coratti Andrea, Correale Pierpaolo, D'Aniello Carlo, Grimaldi Luca, Tanzini Gabriello, Civitelli Serenella, Marsili Stefania, Messinese Simona, Marzocca Giuseppe. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002 Oct;25(5):468–473. doi: 10.1097/00000421-200210000-00009. [DOI] [PubMed] [Google Scholar]
  14. Stojadinovic Alexander, Leung Denis H. Y., Hoos Axel, Jaques David P., Lewis Jonathan J., Brennan Murray F. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002 Mar;235(3):424–434. doi: 10.1097/00000658-200203000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stojadinovic Alexander, Yeh Alice, Brennan Murray F. Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg. 2002 Apr;194(4):436–447. doi: 10.1016/s1072-7515(02)01120-1. [DOI] [PubMed] [Google Scholar]
  16. Weitz Jürgen, Antonescu Christina R., Brennan Murray F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003 Jul 15;21(14):2719–2725. doi: 10.1200/JCO.2003.02.026. [DOI] [PubMed] [Google Scholar]
  17. Youssef Emad, Fontanesi James, Mott Michael, Kraut Michael, Lucas David, Mekhael Hany, Ben-Josef Edgar. Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: analysis of prognostic factors. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):514–519. doi: 10.1016/s0360-3016(02)02942-5. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES